Mundipharma Gains Commercialisation Rights to Allos Therapeutics’ Folotyn® Outside of North America
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 5 (Table of Contents)
Published: 23 May-2011
DOI: 10.3833/pdr.v2011.i5.1473 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Allos Therapeutics has signed a co-development and commercialisation agreement with Mundipharma, potentially worth US$360 M, for its peripheral T-cell lymphoma (PTCL) drug, Folotyn® (pralatrexate injection)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS